Policy / Pricing Trump backs psychedelics for mental health in new executive order Pharmaceutical TechnologyTrump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.Policy / PricingNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Technology Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field. Policy / PricingNeuroscienceRead full story Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: AZ is three for three with COPD hope tozorakimab Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
